Learn More
BACKGROUND RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic prostate adenocarcinoma receiving luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy (RT). METHODS Eligible patients with T-scores of the hip (<-1.0, but >-2.5(More)
  • 1